WHAT ARE THE EFFECTS OF THIS DRUG?
↓ As much as 10% weight loss in one year. (FDA Prescribing Information for Wegovy)
WEGOVY™ is contraindicated in the following conditions:
•A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• People who are allergic to Semaglutide. Serious hypersensitivity reactions have been reported during postmarketing use of semaglutide (Wegovy).
In clinical trials, 6.8% of patients treated with WEGOVY™ and 3.2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions. The most common adverse reactions leading to discontinuation were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%), and diarrhea (0.7% versus 0.1%) for WEGOVY™ and placebo, respectively.
Acute Pancreatitis: Inform patients of the potential risk for acute pancreatitis. Instruct patients to discontinue WEGOVY™ promptly and contact their physician if pancreatitis is suspected (severe abdominal pain that may radiate to the back, and which may or may not be accompanied by vomiting).
Acute Gallbladder Disease: Inform patients of the risk of acute gallbladder disease. Advise patients that substantial or rapid weight loss can increase the risk of gallbladder disease, but that gallbladder disease may also occur in the absence of substantial or rapid weight loss. Instruct patients to contact their healthcare provider for appropriate clinical follow-up if gallbladder disease is suspected. There are several other warnings including risk of increased heart rate, possible worsening of diabetic retinopathy in the eyes, risk of kidney disease, risk of low blood sugars, suicide risk increase, dehydratation, and allergic reactions, and pregnancy precautions that patients should read in the patient information leaflet and discuss with their physician if they have questions. (FDA Prescribing Information for Wegovy)

Generic Name: Semaglutide injection